Collegium Pharmaceutical (COLL) Cash & Equivalents (2014 - 2026)

Collegium Pharmaceutical's Cash & Equivalents history runs 13 years deep, the most recent figure standing at $268.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 179.28% year-over-year to $268.6 million in Q1 2026; TTM through Mar 2026 was $268.6 million, a 179.28% increase from a year earlier, with the FY2025 full-year figure at $231.3 million, up 227.71% from the prior year.
• Cash & Equivalents grew to $268.6 million in Q1 2026 per COLL's latest filing, from $231.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $283.7 million in Q2 2023 and bottomed at $39.0 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $172.9 million (2024), against an average of $174.3 million.
• Across the five-year window, Cash & Equivalents plunged 84.93% in 2024 and jumped 285.26% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $173.7 million in 2022, then surged by 37.57% to $238.9 million in 2023, then tumbled by 70.47% to $70.6 million in 2024, then surged by 227.71% to $231.3 million in 2025, then advanced by 16.17% to $268.6 million in 2026.
• Per Business Quant, the three latest COLL Cash & Equivalents figures stand at $268.6 million (Q1 2026), $231.3 million (Q4 2025), and $150.1 million (Q3 2025).